Overview

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Status:
Not yet recruiting
Trial end date:
2029-01-31
Target enrollment:
Participant gender:
Summary
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Leap Therapeutics, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Treatments:
Pembrolizumab